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INTRODUCTION
Improving care delivery and outcomes for patients with pediatric rheumatic diseases is imperative. Many pediatric rheumatic diseases persist into adulthood, with negative sequelae from the disease or its treatment [1] . A recent cohort study [2 & ] of juvenile idiopathic arthritis (JIA) patients reported 50% with nonpolyarticular categories of disease achieved remission within 5 years of diagnosis; however, far fewer polyarticular JIA patients attained remission (0 to 14%). Long-term studies report that 40-68% of JIA patients are in remission after 17-30 years of follow-up [3, 4 & ], and patients can suffer significant functional limitations and decreased health-related quality of life [3, 5] . Childhood-onset systemic lupus erythematosus (cSLE) is typically more severe than adult-onset SLE [1, 6] and was found to be an independent predictor of increased mortality [7] . Patients with cSLE also have decreased health-related quality of life, including limitations in social capacities and restricted life goals [8 a mean follow-up of 4.2 years [11] . Given therapeutic advances, these outcomes are disappointing. Why aren't more patients achieving disease remission?
Following the reports of suboptimal care from the Institute of Medicine's Committee on the Quality of Healthcare in America, there has been increased focus by healthcare institutions and the public on quality of care [12, 13] . In addition to gaps in healthcare for children in the United States [14] , the quality of care specific to rheumatic diseases has also been inadequate [15, 16] . Organizations like the American College of Rheumatology and the American Board of Pediatrics have supported efforts to improve the care provided to patients with rheumatic conditions, including children [14, 17] . One such effort has been the development of quality measures to aid in quality improvement efforts and quality-focused research [17] . An emerging successful infrastructure for improvement of health outcomes is establishment of collaborative improvement networks that engage healthcare teams, patients, and researchers, contribute data into shared registries, and utilize quality improvement methods to accelerate and spread improvement [14, 18] . Pediatric collaborative improvement networks have shown significantly improved health outcomes and have served as models for other subspecialty network development [19] . The approach is that of a learning health system, in which data gathered from point of care are applied for purposes of quality improvement as well as health services and comparative effectiveness research (CER).
Health outcomes research provides insight into challenges faced by patients with pediatric-onset rheumatic diseases [20,21 & ]. Incorporating patient- ]. Teams track performance on quality measures, including five outcome measures and 11 process measures that were adapted from a publication from 2011 [29] , for the purposes of analysis to guide improvement activities. Both site specific and aggregate data are analyzed monthly via statistical process control charts, allowing PR-COIN to audit and give feedback on performance over time. Improvement science methods employed include developing key driver diagrams with time bound goals, process mapping, and failure mode and effects analysis. The Model for Improvement is used in planning tests of change and highlights three key questions: what are we trying to accomplish?; how will we know that a change is an improvement?; and what changes can we make that will result in improvement [25]? Tests of change can be done with plan-do-study-act cycles, a framework used to perform rapid cycle improvement. Successes and failures are shared via monthly action period calls, biannual face to face learning sessions, PR-COIN website, newsletter, and webinar learning labs such that learning can be spread more rapidly. Certain PR-COIN sites have mapped data captured in the electronic medical record to the central network patient registry for more efficient data entry into the registry, and currently a SmartForm is being developed to facilitate this process (Epic Systems Corporation, Verona, Wisconsin, USA). Linking the electronic medical record to improvement network registries can ease the burden of data entry and further improve care by utilizing an automated report system [30] .
Population management is an intervention that enables overview of characteristics of all patients in
KEY POINTS
Outcomes improvement is accelerated in the context of a networked learning health system approach using data and shared best practices to drive clinical care, quality improvement, and research.
Research is important to evidence generation, and quality improvement networks are instrumental for reliable translation of research into clinical practice.
Partnership between patients/families and healthcare teams is likely to accelerate improvement in care delivery and patient relevant outcomes for children with rheumatic diseases.
Benchmarking is useful to understand system performance but improvement requires planned intervention, tests of change, and learning from the results.
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the registry at a population level. PR-COIN employs an automated reporting function linked to the registry with an electronic tool that allows identification of groups of patients and drill down to individual patients based on criteria included in the registry (demographic characteristics, clinical features, disease status, and medication used) [31] . The population management tool allows individual sites to identify high-risk patients and can be used to generate care gap reports, such as patients not in compliance with quality measures or those lost to follow-up. Acting on these data allows PR-COIN sites to target efforts to close gaps in care across their patient population.
PVP is another intervention proven to improve quality of care [32, 33] . PVP is the act of systematically preparing for a patient visit by verifying compliance with identified recommended processes of care (e.g. performanceof toxicity monitoring labs), identifying areas of need, risk, or gaps in care. PVP allows the healthcare team to more efficiently conduct the clinic visit and free up time to focus on priority needs of the patient.
PR-COIN has also conducted an initiative to enhance SDM [34, 35] . SDM is a process where a provider shares medically reasonable treatment options, and the patient/parent has the opportunity to guide the conversation, considering his/her goals Links personal and population data to researchers and practitioners, dramatically enhances the knowledge base on effectiveness of interventions and provides real-time guidance for superior care in treating and preventing illness
The Model for improvement [25] A guiding approach to improvement projects and tests of change based on three fundamental questions:
1. What are we trying to accomplish?
2. How will we know that a change is an improvement?
3. What changes can we make that will result in improvement?
Previsit planning
The act of systematically preparing for an efficient quality patient visit by gathering necessary information, assessing compliance with recommended processes of care and identifying gaps in care A visual picture of a process being studied to understand how the current process or system works (e.g. flow diagram)
Failure mode and effects analysis [25] Systematic, proactive method of identifying and preventing product and process problems before they occur by using a standardized approach to analysis that includes review of function, failure modes, failure causes, and failure consequences
Patients/families and healthcare team partnering to design, commission or produce a common desired service, object or outcome Quality measure A means to assess performance of an individual or organization on important processes or outcomes
Benchmarking
Comparing individual results and performance on quality measures against best practices in the field and preferences. In PR-COIN, JIA medication treatment choice cards were developed to facilitate discussion about different medication attributes of importance to patients to arrive at informed treatment decisions in alignment with patient goals. Engaging patients and families is an increasingly recognized component for quality improvement in healthcare that is patient-centered [27 & ]. PR-COIN has formed a parent leadership roundtable, Facebook page, parent attendance at action period calls, and robust parent presence at learning sessions. Parents set 90-day goals, hold positions at leadership level and on PR-COIN subcommittees, and contribute novel talent and skills to the network [36] . Through patient/parent engagement, PR-COIN is striving to foster coproduction of network activities whereby healthcare teams and patients/families can work together to produce more desirable outcomes for children with JIA.
Development of a cSLE learning network is underway with plans to build on PR-COIN's successful model, the established infrastructure, and common membership. The preliminary global aim of this collaborative is to promote comprehensive patient and family-centered care to ensure survival, prevent organ damage, and optimize health-related quality of life in all cSLE patients through optimal disease control and comorbidity management [37] . Focus groups have been held at PR-COIN learning sessions in preparation for a design phase before launching a cSLE initiative.
PEDIATRIC RHEUMATOLOGY RESEARCH ORGANIZATIONS
There are several research organizations in the field of pediatric rheumatology that allow multicenter collaboration. The Pediatric Rheumatology Collaborative Study Group is a large North American organization that has a primary aim of conducting high-quality clinical trials of therapeutic agents in children with rheumatic diseases [38] . A similar collaborative based out of Europe with international membership is the Paediatric Rheumatology International Trials Organization (PRINTO) [39, 40] . In addition to medication studies, PRINTO has focused on patient and family education with creation of a website, research training, and development of an autoinflammatory disease registry [40] . The Childhood Arthritis and Rheumatology Research Alliance (CARRA) is a North American organization with large representation that has a mission to conduct collaborative research to prevent, treat, and cure pediatric rheumatic diseases [41] . This organization has a patient registry and several disease-specific work groups. The Paediatric Rheumatology European Society has members throughout Europe and the Middle East with committees focusing on education, clinical affairs, research, allied health professionals, and trainees [42] . There are several other pediatric rheumatology organizations, including Pediatric Vasculitis Initiative, FMF Arthritis Vasculitis and Orphan disease Research in Paediatric Rheumatology, Canadian Alliance of Pediatric Rheumatology Investigators, British Society for Paediatric and Adolescent Rheumatology (BSPAR), and German Society of Pediatric and Adolescent Rheumatology. The research performed by these networks is anticipated to ultimately improve treatment. However, without coordinated effort to change practice and implement best evidence care, there is a significant lag for research findings to become part of clinical practice and wide variability in uptake [43] .
PATIENT-POWERED RESEARCH NETWORKS
The Patient-Centered Outcomes Research Institute (PCORI) was developed in 2010 through the Affordable Care Act to fund comparative clinical effectiveness research [44] . PCORI has funded development of 'patient-powered research networks' that bring together patients/caregivers and researchers to advance patient-centered CER [45] . These networks allow patients and their families to generate data, contribute information, prioritize research questions, and assume leadership roles. In 2013, with funding from PCORI, the Patients, Advocates and Rheumatology Teams Network for Research and Service (PARTNERS) came together to develop a patient-powered research network in pediatric rheumatology [46] . Consortium members include caregiver representatives, CARRA, PR-COIN, the Arthritis Foundation, and the Lupus Foundation of America, with CureJM Foundation joining as a collaborating member in a second phase (2015-18) [47] to continue efforts on building an optimal patient-centered research structure.
CONSENSUS TREATMENT PLANS
Consensus treatment plans (CTPs) are structured guidelines developed from prevalent practice, and agreed upon by clinical experts, that describe different therapeutic approaches to diseases that have a low prevalence or deficient evidence-based practices as in most pediatric rheumatic diseases. CTPs facilitate CER in clinical settings by providing case definitions, recommended collection of data elements at defined visit intervals, and reducing variability in care [48] . Owing to paucity of clinical trial data or head-to-head medication studies in pediatric rheumatic diseases, CARRA has developed CTPs based on collaborative surveys and expert opinion. The initial treatment of moderately severe JDM was the first CTP published by CARRA in 2010, which was prompted after a collaborative survey reported considerable treatment variation [49, 50] . A subsequent CTP developed protocols for the entire JDM treatment course [51] . CTPs for induction therapy of newly diagnosed proliferative lupus nephritis in cSLE were published in 2012 [52] . Two different CTPs have been developed for JIA -one in new-onset systemic JIA [53] and another on new-onset polyarticular JIA [54 & ]. Lastly, CARRA developed standardized treatment plans for juvenile localized scleroderma, in addition to clinical assessment and treatment response criteria using consensus methodology [55] .
Similarly, a European project organized by PRINTO, 'Single Hub and Access point for paediatric Rheumatology in Europe,' is trying to combat the lack of evidence-based guidelines and substantial variation in care of patients with pediatric rheumatic diseases [56] . The first phase of this project included circulation of surveys to PRINTO centers to establish current clinical practices with future plans to develop international best practices from this survey and from the literature.
QUALITY MEASURES
Quality measures represent the minimum standards of care and are 'mechanisms that enable the user to quantify the quality of a selected aspect of care by comparing it to an evidence-based criterion that specifies what is better quality' [57]. Quality measures are developed from evidence and expert opinion and ideally have three properties: importance, scientific soundness, and feasibility [56] . There are three different types of quality measures -structural, process, and outcome measures -with most quality measures being process of care measures given these are actionable items that respond quicker to change [17, 58] .
Quality measures, also known as quality indicators, have been created for rheumatic conditions, including SLE and analgesic use [15, [59] [60] [61] [62] , with the American College of Rheumatology endorsing measures in rheumatoid arthritis, gout, and glucocorticoid-induced osteoporosis [63] . Development of many of these measures involved a threestep approach: literature review, selection of quality measures based on impact or extensive recommendation, then creation of 'if-then-because' statements to reflect the population, process of care measure, and impact on outcomes [59] . A similar method was used to generate quality measures for JIA by Lovell et al. [29] in 2011, which also included timing of assessments, acceptable assessment tools, and performance goals. A total of 12 JIA quality measures were proposed under four domains: disease control, safety monitoring, assessment of self-efficacy and patient/parent satisfaction, and access to care.
PR-COIN adapted these JIA quality measures to track the following process of care measures: measurement of active joint count, arthritis-related pain, physician global assessment of disease activity, health-related quality of life, and physical function; screening for uveitis, medication toxicity, and tuberculosis; and medication counseling [64] . PR-COIN also monitors and tracks JIA outcome measures: clinical inactive disease [65] , clinical remission, clinical Juvenile Arthritis Disease Activity Score [66 & ], no or mild pain level, and optimal physical functioning.
Prior to development of the JIA quality measures in the United States, BSPAR generated 'standards of care' for JIA that were first published in 2009 [67] . These were complemented by a joint effort of BSPAR and the Arthritis and Musculoskeletal Alliance to create 44 standards of care for children and young people with JIA [68] .
In 2011, Brunner, et al. [69] advocated for a comprehensive management plan for cSLE and highlighted clinical and laboratory disease surveillance measures, health maintenance, and education. A total of 26 quality indicators for cSLE were developed with international input in 2013 among nine domains: laboratory testing around time of diagnosis, general prevention, lupus nephritis and hypertension management, medication management, bone health, ophthalmologic surveillance, cardiovascular risk factor education, pregnancy, and neuropsychiatric manifestations [70] . The CARRA JDM Quality Measures Workgroup is also working on establishing quality measures for JDM, taking into consideration patient-reported and patient-centered measures [71] .
BENCHMARKING AND IMPROVEMENT OF QUALITY MEASURES
Benchmarking of quality measures is important to determine ease of measurement in clinical practice and to obtain performance data. A total of 10 centers in the United Kingdom performed retrospective reviews on a total of 428 JIA patients to benchmark the BSPAR and the Arthritis and Musculoskeletal Alliance standards of care [72] . Percentage of patients fulfilling this minimal level of care ranged from 15 to 99%.
Initial benchmarking of cSLE quality indicators demonstrated variability in care of the seven contributing sites -four in the United States, two in Brazil, and one in India [73 & ]. Retrospective review assessed 483 cSLE patients, and large centers had a higher performance in satisfying the quality indicators overall vs. small centers. Example performance on select quality measures is as follows: education on sun avoidance 54-99%, prescription of antimalarial therapy 75-100%, bone mineral density testing if patient received chronic systemic steroids 7-90%, and annual eye examination if on antimalarial therapy 72-96%.
PR-COIN has gone beyond benchmarking and is tracking quality measures over time. There are currently over 3000 JIA patients and over 15 900 encounters in PR-COIN's clinical registry [37] . Two quality measures -documentation of complete joint count and measurement of arthritis-related pain -are meeting or exceeding initial goals [64] . In addition, PR-COIN has improved six process of care measures: measurement of functional ability, monitoring medication toxicity labs, documentation of complete joint count, initial medication counseling for new medications, annual medication counseling, and measurement of health-related quality of life [22, 64] . Many individual sites are also improving quality measures.
CONCLUSION
Improving care delivery and outcomes is essential in pediatric rheumatology given persistence of diseases into adulthood and the gap between recommended care and the care actually received. Research is important, but quality improvement efforts, especially through a learning health network approach, can revolutionize clinical practice.
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